Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Pancreatic Cancer with Liver Metastasis Patient Treated with Integrative Cancer Treatment

췌장암 간전이 환자의 통합 암 치료에 대한 증례보고

  • Ko, Eun-ju (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Myong, Ji-soo (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Kim, Jong-hee (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Park, Ji-hye (East West Cancer Center, Seoul Korean Medicine Hospital of Daejeon University) ;
  • Park, So-jung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Lee, Yeon-weol (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Yoo, Hwa-seung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
  • 고은주 (대전대학교 대전한방병원 동서암센터) ;
  • 명지수 (대전대학교 대전한방병원 동서암센터) ;
  • 김종희 (대전대학교 대전한방병원 동서암센터) ;
  • 박지혜 (대전대학교 서울한방병원 동서암센터) ;
  • 박소정 (대전대학교 대전한방병원 동서암센터) ;
  • 이연월 (대전대학교 대전한방병원 동서암센터) ;
  • 유화승 (대전대학교 대전한방병원 동서암센터)
  • Received : 2021.11.15
  • Accepted : 2021.12.16
  • Published : 2021.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study is to report effects and potential of Integrative Cancer Treatment (ICT) on metastatic pancreatic cancer patient. Methods: A 79-year-old pancreatic cancer patient diagnosed with metastasis on liver visited the Daejeon Korean medicine hospital of Daejeon university East West Cancer Center (EWCC) on May 2021. The patient has been received chemotherapy (gemcitabine plus abraxane) and concurrently treated with ICT since May 2021. The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA19-9) and numeric rating scales (NRS). Laboratory analysis and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0 were used to evaluate the safety of ICT. Results: After treatment, constipation was relieved from NRS 5-6 to 2, both leg numbness was improved from NRS 9 to 2. Tumor size was generally decreased accompanying by reducing the levels of tumor markers. There were no severe adverse events induced by ICT based on NCI CTCAE version 5.0. Conclusion: This case study suggests that ICT in combination with chemotherapy may help in the treatment of patients with metastatic pancreatic cancer.

Keywords

Acknowledgement

이 연구는 보건복지부와 한국 보건산업진흥원 한의약선도기술개발사업의 지원에 의하여 이루어진 것임(과제고유번호 : HI19C1046).

References

  1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69:7-34, 2019. https://doi.org/10.3322/caac.21551
  2. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA: a cancer journal for clinicians 70:7-30, 2020. https://doi.org/10.3322/caac.21590
  3. Roe, J. S. et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 170:875-888 e820, 2017. https://doi.org/10.1016/j.cell.2017.07.007
  4. Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49:358-366, 2017. https://doi.org/10.1038/ng.3764
  5. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 395:2008-2020, 2020. https://doi.org/10.1016/S0140-6736(20)30974-0
  6. Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Buchler MW, et al. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Pancreatol. 3:1-11, 2020. https://doi.org/10.1097/JP9.0000000000000040
  7. D.V. Catenacci, M.R. Junttila, T. Karrison, N. Bahary, M.N. Horiba, S.R. Nattam, R. Marsh, J. Wallace, M. Kozloff, L. Rajdev, D. Cohen, J. Wade, B. Sleckman, H. J. Lenz, P. Stiff, P. Kumar, P. Xu, L. Henderson, N. Takebe, R. Salgia, X. Wang, W. M. Stadler, F.J. de Sauvage, H.L. Kindler, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J. Clin. Oncol. 33:4284-4292, 2015. https://doi.org/10.1200/JCO.2015.62.8719
  8. Siegel, R.L. et al. Cancer statistics, 2017. CA Cancer J. Clin. 67:7-30, 2017. https://doi.org/10.3322/caac.21387
  9. Park BK, Yoo HS, Lee YW, Han SS, Cho JH, Son CG, Cho CK. Retrospective cohort analysis for lung cancer patients treated with Wheel Balance Therapy (WBT). Korean J Orient Int Med. 19(2):45-56, 2009.
  10. Schwartz LH, Litie' re S, de Vries E, et al: RECIST 1.1: Update and clarification-From the RECIST committee. Eur J Cancer 62:132-137, 2016 https://doi.org/10.1016/j.ejca.2016.03.081
  11. National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/.
  12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
  13. Crawford HC, Pasca di Magliano M, Banerjee S. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Gastroenterology. 156:2073-2084, 2019. https://doi.org/10.1053/j.gastro.2018.12.042
  14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 71(1):7-33, 2021. https://doi.org/10.3322/caac.21654
  15. Walter, F. M. et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): A prospective cohort study. Lancet Gastroenterol. Hepatol. 1, 298-306, 2016. https://doi.org/10.1016/S2468-1253(16)30079-6
  16. United States National Cancer Institute. Pancreatic cancer: statistics. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics, 2018.
  17. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancre-atic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 18:688, 2018. https://doi.org/10.1186/s12885-018-4610-4
  18. Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 371:1039-1049, 2014. https://doi.org/10.1056/NEJMra1404198
  19. Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY and Kim YS: Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact. 233:25-34, 2015. https://doi.org/10.1016/j.cbi.2015.03.016
  20. Sriramulu Elluru, Jean-Paul Duong Van Huyen, Sandrine Delignat, Fabienne Prost, Jagadeesh Bayry, Michel D. Kazatchkine, Srini V. Kaveri, Arzneimittelforschung. 56(6):461-466, 2006 https://doi.org/10.1055/s-0031-1296813
  21. E. Giacomini, M. Severa, M. Cruciani, M.P. Etna, F. Rizzo, M. Pardini, C. Scagnolari, E. Garaci, E.M. Coccia, Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists, Expert Opin. Biol. Ther. 15:S59-S70, 2015.
  22. Zee J. Heating the patient: a promising approach. Ann Oncol 13(8):1173-1184, 2002. https://doi.org/10.1093/annonc/mdf280
  23. Y. Miyasaka, T. Ohtsuka, R. Kimura, R. Matsuda, Y. Mori, K. Nakata, D. Kakihara, N. Fujimori, T. Ohno, Y. Oda, M. Nakamura, Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery, Annals of Surgical Oncology. Springer New York LLC March. 1528-1534, 2019.
  24. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, et al. Inhibition of HIF-1 by PX-478 enhances the anti-tumor effect of gemcitabineby inducing immunogenic cell death in pancreatic ductal ade-nocarcinoma. Oncotarget. 6(4):2250-2262, 2015. https://doi.org/10.18632/oncotarget.2948
  25. Renia M, Bonettoa E, Cordio S, Passoni P, Carlo Milandri C, Cereda S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a Phase III randomized trial. Pancreatology. 6(5):454-463, 2006. https://doi.org/10.1159/000094563